HERON THERAPEUTICS INC (HRTX)
US4277461020 - Common Stock
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company...
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's...
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S....
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing...
HRTX Stock Earnings: Heron Therapeutics Misses EPS, Beats Revenue for Q2 2024
HRTX stock results show that Heron Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
HRTX Stock Earnings: Heron Therapeutics Misses EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Heron Therapeutics (NASDAQ:HRTX) just reported results for the second quarter o...
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results...
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call...
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that ZYNRELEF®...
Noteworthy Tuesday Option Activity: HRTX, HOG, PANW
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the FDA...
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior...
Interesting HRTX Call Options For May 17th
HRTX Stock Earnings: Heron Therapeutics Beats EPS, Beats Revenue for Q1 2024
HRTX stock results show that Heron Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Commit To Purchase Heron Therapeutics At $2, Earn 17% Annualized Using Options
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on...
Commit To Buy Heron Therapeutics At $2, Earn 22.4% Annualized Using Options
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer...
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results...
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call...
Heron Therapeutics rises on securing label expansion for pain therapy (NASDAQ:HRTX)
Heron Therapeutics' shares surge on FDA approval of Zynrelef indication expansion for postoperative pain management solution, boosting prospects for the...
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration...
The 3 Most Undervalued Biotech Stocks to Buy in January
These are a number of undervalued biotech companies that investor should possibly look to add to their portfolios.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning!
Heron stock gains on sales deal for pain therapy Zynrelef
Heron Therapeutics (HRTX) stock surges 16% as it partners with CrossLink Life Sciences to expand sales network for its pain therapy Zynrelef. Read more here.